A comparative study of 500 mg BID and 250 mg BID of prophylactic oral ganciclovir in post-kidney transplant ''CMV at risk'' recipients

By Yang H.C.   Holman M.J.   Langhoff E.   Dellock C.A.   Gupta M.   Ulsh P.J.   Ahsan N.  

Transplantation Proceedings, Vol. 31, Iss. 1, 1999-02 ,pp. : 1125-1126

Elsevier

Access to resources Recommend Favorite

Effective oral ganciclovir prophylaxis against cytomegalovirus disease in heart transplant recipients

By Mullen G.M.   Silver M.A.   Malinowska K.   Lawless C.E.   Lichtenberg R.C.   Barath P.C.   O'Keefe P.J.   Robinson J.A.   Yeldandi V.  

Transplantation Proceedings, Vol. 30, Iss. 8, 1998-12 ,pp. : 4110-4112

Elsevier

Access to resources Recommend Favorite

Use of combination cytomegalovirus immune globulin plus ganciclovir for prophylaxis in CMV-seronegative liver transplant recipients of a CMV-seropositive donor organ: a multicenter, open-label study

By Snydman D.R.   Falagas M.E.   Avery R.   Perlino C.   Ruthazer R.   Freeman R.   Rohrer R.   Fairchild R.   O'Rourke E.   Hibberd P.   Werner B.G.  

Transplantation Proceedings, Vol. 33, Iss. 4, 2001-06 ,pp. : 2571-2575

Elsevier

Access to resources Recommend Favorite

Prophylaxis of cytomegalovirus disease with ganciclovir or anti-CMV immunoglobulin in renal transplant recipients who receive antilymphocytic antibodies as induction therapy

By Morales E.   Andres A.   Gonzalez E.   Herrero J.C.   Munoz M.A.   Ortiz M.   Espejo B.   Lumbreras C.   Morales J.M.   Aguado J.M.  

Transplantation Proceedings, Vol. 34, Iss. 1, 2002-02 ,pp. : 73-74

Elsevier

Access to resources Recommend Favorite

Cost analysis of four strategies for prevention of CMV infection in liver transplant recipients

By Post A.B.   Mulligan D.C.   Bush W.  

Transplantation Proceedings, Vol. 30, Iss. 5, 1998-08 ,pp. : 2102-2103

Elsevier

Access to resources Recommend Favorite